Vis enkel innførsel

dc.contributor.advisorRichardsen, Elin
dc.contributor.authorStikbakke, Einar
dc.date.accessioned2022-03-02T08:42:21Z
dc.date.available2022-03-02T08:42:21Z
dc.date.issued2022-03-31
dc.description.abstract<p><i>Background/Aims:</i> Prostate cancer (PCa) is the most common cancer among men in Norway as well as world-wide, and a major cause of health loss and death with 1.4 million new cases and 375 000 deaths world-wide in 2020. Biological mechanisms involved in PCa development are mainly unknown, but chronic inflammation, one hallmark of cancer development, has been questioned to play a key role in PCa development. This thesis aimed to explore whether markers that may be linked to inflammation, such as high sensitive-C-reactive protein (hs-CRP) and white blood cell count (WBC), systolic and diastolic blood pressure (BP) and miR-24-1-5p, a subtype of microRNA, may play a role in PCa development, recurrence and mortality. <p><i>Materials and methods:</i> The Prostate Cancer Study throughout Life (PROCA-life) is a population-based cohort study, a sub study of the Tromsø Study and the present thesis includes all men, who were enrolled in the Tromsø Study between 1994 and 2016 (Tromsø 4-7). The procedures were almost identical, and assessments were done by trained research technicians. By linkage to the Cancer Registry of Norway and Norwegian Cause of Death Registry, all PCa cases and death among the participating men were identified. Detailed histopathological and medical records were obtained. Cox proportional hazard regression models were used to study the association between prediagnostic WBC and hs-CRP in serum (Paper I), prediagnostic blood pressure (Paper II) and PCa risk and prognosis. We collected prostatectomy tissue from 142 PCa patients, and we studied the influence of miR-24-1-5p regarding aggressiveness and prognosis in men diagnosed with PCa. <p><i>Results:</i> We observed a positive dose-response relationship between hs-CRP and PCa risk. Men with an increase in hs-CRP between two measurements had a 36% increased risk of PCa, compared to men with no change or decrease in hs-CRP. Men with a high systemic inflammatory score (combination of WBC and hs-CRP) had a 68% higher risk of being diagnosed with metastatic disease compared to men with lower scores. Men (> 45 years) with a systolic BP > 150 mmHg had a 35% increased risk of PCa compared to men with a normal systolic BP (< 130 mmHg). Among PCa cases, men with systolic BP > 150 mmHg had a 49% increased overall mortality compared to men with a normal systolic BP. PCa patients with a high miR-24-1-5p expression in the tissue had a doubled risk of recurrence compared to patients with low miR-24-1-5p expression. <p><i>Conclusion:</i> Our results suggest that hs-CRP alone or in combination with WBC may be a useful inflammation-related biomarker for PCa risk and prognosis, and systolic and diastolic BP may be important factors when balancing disease management in PCa patients. Moreover, a high expression of miR-24-1-5p is associated with an increased risk of recurrence of PCa after radical prostatectomy. Systemic inflammation might be the common link between these factors, but further research is needed.en_US
dc.description.doctoraltypeph.d.en_US
dc.description.popularabstractProstate cancer is the most common cancer among men in Norway and world-wide. Our research focuses on how factors linked to inflammation in the body affects prostate cancer development and prognosis. The Prostate Cancer Study throughout life (PROCA-life), is a population-based cohort study, a sub study of the Tromsø Study, and includes men who were enrolled in the Tromsø Study (1994 -2016), where factors linked to inflammation were measured. Prostate cancer cases were identified through a linkage to the Cancer Registry of Norway. Our findings suggest that men with factors associated with systemic inflammation measured in blood samples have increased risk of prostate cancer. We observed that men with high blood pressure had increased risk of prostate cancer, and that blood pressure may influence risk of dying among prostate cancer patients. We also observed that the molecule miR-24-1-5p in prostate tissue can be used to identify men with increased risk of recurrence of prostate cancer. Thus, blood pressure may be important when balancing disease management in prostate cancer patients, while our findings related to inflammatory factors and miR-24-1-5p need to be investigated in more studies.en_US
dc.description.sponsorshipUiT Norges arktiske universiteten_US
dc.identifier.urihttps://hdl.handle.net/10037/24212
dc.language.isoengen_US
dc.publisherUiT The Arctic University of Norwayen_US
dc.publisherUiT Norges arktiske universiteten_US
dc.relation.haspart<p>Paper I: Stikbakke, E., Richardsen, E., Knutsen, T., Wilsgaard, T., Giovannucci, E.L., McTiernan, A., … Thune, I. (2020). Inflammatory serum markers and risk and severity of prostate cancer: The PROCA-life study. <i>International Journal of Cancer, 147</i>(1), 84-92. Also available in Munin at <a href=https://hdl.handle.net/10037/17876>https://hdl.handle.net/10037/17876</a>. <p>Paper II: Stikbakke, E., Schirmer, H., Knutsen, T., Støyten, M., Wilsgaard, T., Giovannucci, E.L., … Thune, I. (2021). Systolic and diastolic blood pressure, prostate cancer risk, treatment and survival. The PROCA-life Study. <i>Cancer Medicine, 11</i>(4), 1005-1015. Also available in Munin at <a href=https://hdl.handle.net/10037/23833>https://hdl.handle.net/10037/23833</a>. <p>Paper III: Stikbakke, E., Wilsgaard, T., Haugnes, H.S., Pedersen, M.I., Knutsen, T., Støyten, M., … Richardsen, E. Expression of microRNA miR-24-1-5p in tumor tissue influence prostate cancer recurrence. The PROCA-life Study. (Manuscript under review). Now published in <i>Cancers, 2022, 14</i>(5), 1142, available at <a href=https://doi.org/10.3390/cancers14051142> https://doi.org/10.3390/cancers14051142</a>.en_US
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0en_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.subjectVDP::Medisinske Fag: 700::Helsefag: 800::Epidemiologi medisinsk og odontologisk statistikk: 803en_US
dc.subjectVDP::Medical disciplines: 700::Health sciences: 800::Epidemiology medical and dental statistics: 803en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectProstate canceren_US
dc.titleInflammation, hypertension, and microRNA and Prostate Cancer. The Prostate Cancer throughout life (PROCA-life) studyen_US
dc.typeDoctoral thesisen_US
dc.typeDoktorgradsavhandlingen_US


Tilhørende fil(er)

Thumbnail
Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)